Abstract:Objectives To investigate if Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism influence Hcy lowering response to folic acid treatment in hypertensive Chinese adults. Methods This study was part of a multicenter, randomized, double-blind, controlled trial in China. A total of 454 subjects with mild or moderate essential hypertension were assigned randomly to three treatment groups: (1) enalapril tablet only (10 mg, control group); (2) enalapril (10 mg)–folic acid (0.4 mg) tablet (low FA group); (3) enalapril (10 mg)–folic acid (0.8 mg) tablet (high FA group), once daily for 8 weeks. Blood homocysteine concentrations were measured at three time points: baseline, 4th week, and 8th week of the trial. Individual MTHFR C677T genotype was determined using ABI Taqman platform. Results After 8 weeks of treatment, subjects with TT genotype had significantly greater Hcy lowering response than did subjects with TC/CC genotype (22.9% vs. 13.7% reduction in low FA group and 29% vs. 13.7% reduction in high FA group). Despite greater response to the 8-week FA treatment, subjects with TT genotype continued to have higher Hcy level than subjects with CT or CC genotype. Conclusions This randomized controlled trial demonstrated that MTHFR C677T polymorphism is an important determinant of Hcy lowering response to FA treatment, and post 8-week-treatment Hcy level in the hypertensive Chinese adults. Our data underscored the need to account for MTHFR C677T polymorphism in assessing individual susceptibility to respond to FA treatment. Objectives To investigate if Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism influence Hcy lowering response to folic acid treatment in hypertensive Chinese adults. Methods This study was part of a multicenter, randomized, double-blind, controlled trial in China. A total of 454 subjects with mild or moderate essential hypertension were assigned randomly to three treatment groups: (1) enalapril tablet only (10 mg, control group); (2) enalapril (10 mg)–folic acid (0.4 mg) tablet (low FA group); (3) enalapril (10 mg)–folic acid (0.8 mg) tablet (high FA group), once daily for 8 weeks. Blood homocysteine concentrations were measured at three time points: baseline, 4th week, and 8th week of the trial. Individual MTHFR C677T genotype was determined using ABI Taqman platform. Results After 8 weeks of treatment, subjects with TT genotype had significantly greater Hcy lowering response than did subjects with TC/CC genotype (22.9% vs. 13.7% reduction in low FA group and 29% vs. 13.7% reduction in high FA group). Despite greater response to the 8-week FA treatment, subjects with TT genotype continued to have higher Hcy level than subjects with CT or CC genotype. Conclusions This randomized controlled trial demonstrated that MTHFR C677T polymorphism is an important determinant of Hcy lowering response to FA treatment, and post 8-week-treatment Hcy level in the hypertensive Chinese adults. Our data underscored the need to account for MTHFR C677T polymorphism in assessing individual susceptibility to respond to FA treatment.

Methylenetetrahydrofolate reductase variants associated with hypertension and cardiovascular disease interact with dietary polyunsaturated fatty acids to modulate plasma homocysteine in puerto rican adults.

Interactions between genetic variants of folate metabolism genes and lifestyle affect plasma homocysteine concentrations in the Boston Puerto Rican population.

Mat1a Variants Modulate the Effect of Dietary Fatty Acids on Plasma Homocysteine Concentrations

Relationship between MTHFR C677T Polymorphisms and Susceptibility of Digestive System Cancer and Coronary Heart Disease

Mthfr C677t Polymorphism And Risk Of Congenital Heart Defects: Evidence From 29 Case-Control And Tdt Studies

Effect of n-3 polyunsaturated fatty acid on gene expression of the critical enzymes involved in homocysteine metabolism

Genetic Variants at PSMD3 Interact with Dietary Fat and Carbohydrate to Modulate Insulin Resistance

Association of Methylenetetrahydrofolate Reductase C677T Polymorphism with Blood Homocysteine and Response to Folic Acid Treatment in Hypertensive Chinese Adults

Evidence on the Causal Link Between Homocysteine and Hypertension from a Meta-Analysis of 40 173 Individuals Implementing Mendelian Randomization.

Effect of methylenetetrahydrofolate reductase C677T polymorphism on serum folate but not vitamin B12 levels in patients with H-type hypertension

Effect Of Polyunsaturated Fatty Acids On Homocysteine Metabolism Through Regulating The Gene Expressions Involved In Methionine Metabolism

Plausible Relationship Between Homocysteine and Obesity Risk Via MTHFR Gene: a Meta-Analysis of 38,317 Individuals Implementing Mendelian Randomization

Associations of Common Variants in Methionine Metabolism Pathway Genes with Plasma Homocysteine and the Risk of Type 2 Diabetes in Han Chinese

Dmso_a_205379 1201..1212

Methylenetetrahydrofolate Reductase C677t Polymorphism, Hypertension And Risk Of Stroke: A Prospective, Nested Case-Control Study

Association of MTHFR C677T, MTHFRA1298C, and MTRRA66G Gene Polymorphisms with Hyperhomocysteinemia and Its Modulation by the Combined Effect of Vitamin B12 and Folate in Chinese Population with Hypertension

Single nucleotide polymorphism of MTHFR rs1801133 associated with elevated Hcy levels affects susceptibility to cerebral small vessel disease

Polyunsaturated Fatty Acids (PUFA) Modulate Association Between PIK3CA‐KCNMB3 Variants and Insulin Resistance

Methylenetetrahydrofolate Reductase Gene C677T Polymorphism–Dietary Pattern Interaction on Hyperhomocysteinemia in a Chinese Population: A Cross-Sectional Study

MTHFR C677T and MTR A2756G polymorphisms and the homocysteine lowering efficacy of different doses of folic acid in hypertensive Chinese adults

Homocysteine and All-Cause Mortality in Hypertensive Adults Without Pre-Existing Cardiovascular Conditions: Effect Modification by MTHFR C677T Polymorphism.